CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ALLENEDRUG project aims to develop a new series of ligands targeting G-protein-coupled receptors to create safer therapies for type 2 diabetes. By utilizing a synthetic method for producing enantiomerically enriched compounds, the project seeks to evaluate their potential as GPR40 agonists while investigating their…
Type 2 Diabetes is a chronic disease affecting more than 450 million people world-wide and is still an unmet medical need. PPAR´s(Peroxisome Proliferator-Activated Receptors) and G-protein-coupled receptors (GPCR) FFARs (Free Fatty Acid Receptors) are wellclinical validated targets for type-2 diabetes.
Although selective GPR40 agonists have reached clinical phase III, the trials wererecently terminated due to signs of liver toxicity in patients. ALLENEDRUG is designed to provide a new chemical s…
UNIVERSIDAD AUTONOMA DE MADRID
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
